1.Maes, M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11–38.
2.Gregor, MF, Hotamisligil, GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415–445.
3.Wellen, KE, Hotamisligil, GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111–1119.
4.Stuart, MJ, Baune, BT. Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev 2012;36:658–676.
5.Mezuk, Bet al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008;31:2383–2390.
6.Rotella, F, Mannucci, E. Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Res Clin Pract 2013;99:98–104.
7.Fried, SK, Bunkin, DA, Greenberg, AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847–850.
8.Shoelson, SE, Herrero, L, Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169–2180.
9.Plata-Salaman, CR. Immunomodulators and feeding regulation: a humoral link between the immune and nervous systems. Brain Behav Immun 1989;3:193–213.
10.Hotamisligil, GS, Shargill, NS, Spiegelman, BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87–91.
11.Dowlati, Yet al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446–457.
12.Capuron, L, Miller, AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011;130:226–238.
13.Kubera, Met al. A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. Brain Behav Immun 2013;31:96–104.
14.Puntener, Uet al. Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia. J Neuroinflammation 2012;9:146.
15.Cani, PDet al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–1772.
16.Porsolt, RD, Le Pichon, M, Jalfre, M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730–732.
17.Cryan, JF, Markou, A, Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238–245.
18.Benjamini, Y, Hochberg, Y. Controlling the false discovery rate – a practical and powerful approach to multiple testing. J R Statist Soc B-Methodological 1995;57:289–300.
19.Dantzer, R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009;29:247–264.
20.Haley, PJ. Species differences in the structure and function of the immune system. Toxicology 2003;188:49–71.
21.Grossman, C. Possible underlying mechanisms of sexual dimorphism in the immune response, fact and hypothesis. J Steroid Biochem 1989;34:241–251.
22.Kehl, LJ, Kovacs, KJ, Larson, AA. Tolerance develops to the effect of lipopolysaccharides on movement-evoked hyperalgesia when administered chronically by a systemic but not an intrathecal route. Pain 2004;111:104–115.